Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Europe’s largest biotech company Actelion said it will acquire Ceptaris, a privately held U.S.-based specialty pharmaceutical company developing a topical drug, Valchlor, to treat a form of cancer. The move is an attempt by Actelion to seek new products to replace top-seller Tracleer, a treatment for pulmonary arterial hypertension (PAH), which makes up about 87 percent of sales. Allschwil-based Actelion said it already paid Ceptaris $25 million and will pay another $225 million when the deal closes.
Help employers find you! Check out all the jobs and post your resume.
